The ability to analyze complex networks that reflect biological processes and molecular interactions is critical for drug development. A key factor is determining the structure of these networks and detecting interconnected communities. Graph analytics can provide a powerful tool when examining patient symptoms and outcomes for medical analysis. Quantum computing has the potential to transcend limitations of existing systems and improve insight and results. QCI’s QGraph, a component of Qatalyst, empowers drug analysts to solve the most computationally expensive graph problems.

The partnership offers IPQ early access to the QDetect community-detection technology of QGraph. The resulting “next generation phenotypes” (NGP) will be used to “re-diagnose” patients in failed clinical trials to identify responsive patient subgroups; optimize payor reimbursement guidelines to reduce unnecessary testing and ineffective patient treatment; and to enhance clinical decision support for earlier, more accurate diagnoses and improved patient management.

The US has 12 million diagnostic errors per year resulting in 40,000 – 80,000 deaths, and at a cost of $750B to healthcare. Clinical trials cost an average of $1B, yet less than 15% of them succeed. Both misdiagnosis and missed-diagnoses contribute to these errors, reflecting the need for more effective, efficient, and accurate diagnoses. The innovative IPQ modeling approach, along with Qatalyst, has the potential to address these critical challenges for pharma (recovering failed clinical trials and improving trial design), for insurance/payors (improving reimbursement policies to reduce ineffective tests and treatments) and patients (improving diagnosis, treatment and outcomes.)

“We believe that this new approach, optimized and enhanced with our quantum computing software, has significant clinical and commercial value,” said Robert Liscouski, CEO of QCI. “By enabling more effective patient management and the development of more directed and cost-effective treatments, we are committed to providing value with quantum computing for businesses today.”

This partnership will focus on and utilize a novel technique developed and validated by IPQ for preserved ejection heart failure (HFpEF). QCI and IPQ have closely collaborated to migrate the NGP algorithm to run on QCI’s Qatalyst quantum optimization software and its QDetect community detection graph analysis.

While today’s quantum computers (quantum processing units or “QPUs”) alone cannot yet scale to solve enterprise-class problems, QCI’s Qatalyst currently accelerates the value, accuracy and timeliness of classical computing systems, thanks to the application of powerful quantum-ready techniques. It can accept constrained optimization problems, graph models, and now community detection for computation. It includes seamless access to QPUs via Amazon Braket, including D-Wave, IonQ, and Rigetti. QCI also now offers access to IBM quantum computers via the IBM cloud.

The enhanced Qatalyst-powered version of the NGP algorithm enables a much larger number of features, exceeding the current classical computing limitations, to be analyzed in a manner applicable to other conditions. This provides a new basis for the development of more directed and effective diagnostics for physicians and therapeutics through academic and industry research.

“Qatalyst’s new community detection algorithm and QCI’s strong technical team have uniquely enabled IPQ to address several critical challenges in dealing with real world data including its inherent sparseness of data and its diversity, complexity and potential scale,” said IPQ’s Managing Director, Michael Liebman, PhD. “Working with QCI, IPQ has been able to address the need to integrate the true complexity of the patient, of the disease and of the practice of medicine.”

About IPQ Analytics
IPQ Analytics, LLC (“IPQ”) is an emerging digital healthcare analytics company collaborating with patients, physicians, pharma and payors to optimally extract insights from the complexities that exist within real world healthcare. IPQ converts data into knowledge through use of its novel knowledge mapping of the patient journey uniquely incorporating how clinical history, lifestyle/environment, social/cultural/trust determinants and the practice of medicine impact that journey. IPQ’s ability to technically develop and stratify a patient journey (from health through disease) using “next generation phenotyping” (NGP), significantly improves clinical decision support, drug development and clinical trial recovery, reimbursement guidelines, and patient outcomes. IPQ’s disease agnostic approach is being successfully applied in multiple sclerosis, heart failure, breast cancer and prematurity/infant-maternal morbidity and mortality, to effectively address women’s health.

About Quantum Computing Inc.
Quantum Computing Inc. (QCI) (OTCQB: QUBT) is focused on accelerating the value of quantum computing for real-world business solutions. The company’s flagship product, Qatalyst, is the first software to bridge the power of classical and quantum computing, hiding complexity and empowering SMEs to solve complex computational problems today. QCI’s expert team in finance, computing, security, mathematics and physics has over a century of experience with complex technologies; from leading edge supercomputing innovations, to massively parallel programming, to the security that protects nations. Connect with QCI on LinkedIn and @QciQuantum on Twitter.